(RTTNews) - Protara Therapeutics, Inc. (TARA) announced the FDA has granted Fast Track designation to Intravenous Choline Chloride, the investigational IV phospholipid substrate replacement therapy, ...
(RTTNews) - Protara Therapeutics, Inc. (TARA) has dosed the first patient in its pivotal Phase 3 registrational THRIVE-3 trial evaluating intravenous (IV) Choline Chloride in patients dependent on ...
IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S. Approximately 80% of PN patients are choline deficient, which ...
The FDA has granted Fast Track designation to intravenous choline chloride (Protara Therapeutics), an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure ...
(RTTNews) - Protara Therapeutics, Inc. (TARA) announced Friday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on a registrational path forward for intravenous (IV) ...
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...
Please provide your email address to receive an email when new articles are posted on . ArTara Therapeutics has completed an end-of-phase 2 meeting with the FDA to discuss a phase 3 study of ...
May 26 (Reuters) - Protara Therapeutics Inc: * PROTARA THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FROM U.S. FDA FOR INTRAVENOUS CHOLINE CHLORIDE FOR THE TREATMENT OF INTESTINAL FAILURE ASSOCIATED ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results